Jazz Pharmaceuticals (JAZZ) jumped 2.56% yesterday.
Jazz, whose drugs include treatments for pain and narcolepsy, reports Q2 results after today’s close. Analysts forecast a 39% increase in earnings to $1.52 a share. Sales for the period are expected to jump 68% to $208.7 million.
With your September 2013 $70 call options (JAZZ130921C00070000) now up 57.54%, I recommend that you sell half of your options here to lock in solid gains ahead of tonight’s earnings announcements.
With the JAZZ stock up 34.82% since my initial recommendation, raise your stop to $75.50 to lock in at least a 30% gain in the stock.
This content is for paid subscribers only. To gain access subscribe to one of our…
It is hard to find a seasoned investor who doesn’t believe the stock market is…
No one believes a financial disaster can strike… until it’s too late. That’s bizarre, considering…
The Options Industry Council is a resource used to educate investors about the benefits and…
The put-call parity is the relationship that exists between put and call prices of the…
“It’s not a stock market, it’s a market of stocks.” -- “Maxims of Wall Street,”…